{"resourceType":"ValueSet","id":"2.16.840.1.113883.3.3616.200.110.102.4017","meta":{"versionId":"5","lastUpdated":"2020-12-17T01:00:36.000-05:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4017","version":"20201217","name":"COVID19 ICD10PCS Value Set for Administration of Sarilumab","status":"active","date":"2020-12-17T01:00:36-05:00","publisher":"Clinical Architecture","compose":{"include":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","concept":[{"code":"XW033G5","display":"Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"},{"code":"XW043G5","display":"Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5"}]}]},"expansion":{"identifier":"urn:uuid:a084e3ef-a3f9-47e7-918b-bf4892a47efe","timestamp":"2022-06-10T06:23:36-04:00","total":2,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW033G5","display":"Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5"},{"system":"http://www.icd10data.com/icd10pcs","version":"2022","code":"XW043G5","display":"Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5"}]}}